前列腺癌患者的眼部症状
一名66岁去势抵抗性前列腺癌患者接受F-PSMA 1007 PET/CT显示颅骨、胸部、脊柱、骨盆和四肢广泛PSMA阳性骨转移,随后接受Lu-PSMA-617治疗。24小时SPECT/CT显示左眼附近额外活性,第一周期后因疼痛行活检,第二治疗周期后该活性在SPECT/CT上不可见,眼痛缓解。
要点
- 去势抵抗性前列腺癌患者F-PSMA 1007 PET/CT显示颅骨、胸部、脊柱、骨盆和四肢广泛PSMA阳性骨转移。
- Lu-PSMA-617治疗后24小时SPECT/CT显示左眼附近额外活性,F-PSMA未见。
- 第一周期后因疼痛行活检,第二治疗周期后SPECT/CT上该活性不可见,眼痛缓解。
核心结论
- Lu-PSMA-617治疗后24小时SPECT/CT显示左眼附近额外活性,第二治疗周期后该活性不可见且眼痛缓解。
研究设计与样本
- 66岁去势抵抗性前列腺癌患者,接受F-PSMA 1007 PET/CT和Lu-PSMA-617治疗,第一周期后因疼痛行活检。
主要发现
- F-PSMA 1007 PET/CT显示颅骨、胸部、脊柱、骨盆和四肢广泛PSMA阳性骨转移。
- Lu-PSMA-617治疗后24小时SPECT/CT显示左眼附近额外活性,F-PSMA未见。
- 第一周期后因疼痛行活检,第二治疗周期后SPECT/CT上该活性不可见,眼痛缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 66-year-old man with castration-resistant prostate cancer was evaluated with F-prostate-specific membrane antigen (PSMA) 1007 PET/CT, which revealed extensive PSMA-positive skeletal metastases in the skull, thorax, spine, pelvis, and extremities. He was then treated Lu-PSMA-617 therapy. Twenty-four-hour SPECT/CT revealed additional activity not seen with F-PSMA adjacent to his left eye. The lesion was biopsied after the first cycle due to pain. This activity was not visible on SPECT/CT after the second treatment cycle, and his eye pain has resolved.
引用
- Kairemo K, Kangasmäki A, Joensuu T, et al. Eye Symptoms in a Patient With Prostate Cancer. Clin Nucl Med. 2020. PMID: 32149800. doi:10.1097/RLU.0000000000002982
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。